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Chronic inflammation is a contributing factor to most
life-shortening human diseases. However, the mo-
lecular and cellular mechanisms that sustain chronic
inflammatory responses remain poorly understood,
making it difficult to treat this deleterious condition.
Using a mouse model of age-dependent inflamma-
tion that results from a deficiency in miR-146a, we
demonstrate that miR-155 contributed to the pro-
gressive inflammatory disease that emerged as
Mir146a/ mice grew older. Upon analyzing lym-
phocytes from inflamed versus healthy middle-
aged mice, we found elevated numbers of T follicular
helper (Tfh) cells, germinal center (GC) B cells, and
autoantibodies, all occurring in a miR-155-depen-
dent manner. Further, Cd4-cre Mir155fl/fl mice were
generated and demonstrated that miR-155 functions
in T cells, in addition to its established role in B cells,
to promote humoral immunity in a variety of contexts.
Taken together, our study discovers that miR-146a
and miR-155 counterregulate Tfh cell development
that drives aberrant GC reactions during chronic
inflammation.
INTRODUCTION
Chronic, low-grade inflammation is driven by sustained produc-
tion of inflammatory factors such as cytokines, reactive oxygen
species, and autoantibodies and is associated with seven of
the top ten causes of mortality—such as heart disease, neurode-
generation, metabolic disorders, autoimmunity, and cancer
(Akbaraly et al., 2013; Howcroft et al., 2013; Michaud et al.,
2013)—in the United States. This deleterious condition, which
typically lacks clinical symptoms, can cause damage to impor-
tant organ systems over time and serve as a primer for many
age-related disorders. Despite our growing knowledge of
immune regulation during acute inflammatory responses, our
understanding of molecular and cellular mechanisms governing
chronic, low-grade inflammation remains tenuous. This defi-ciency has prevented the development of targeted therapies to
reduce chronic inflammation and the plethora of disorders asso-
ciated with one’s inflammatory status during the aging process.
By the year 2050, it is projected that those 60 years and older will
make up 22% of the world’s population, compared to only 10%
in the year 2000 (Dorshkind et al., 2009). Thus, finding therapeu-
tic solutions to chronic inflammatory conditions has become
more important than ever before.
It is now appreciated that most of the human genome is tran-
scribed into noncoding RNAs that carry out diverse cellular func-
tions including differentiation, survival, and proliferation (Esteller,
2011). Among noncoding RNAs, microRNAs (miRNAs) regulate
gene expression posttranscriptionally and have been shown to
modulate awide range of biological systems (Mendell andOlson,
2012). Further, several miRNAs have been shown to control
inflammation in young mice subjected to infection by pathogens
or during antigen-induced autoimmunity (Baumjohann et al.,
2013; Kang et al., 2013; O’Connell et al., 2010b; Oertli et al.,
2011; Rodriguez et al., 2007). Despite their emerging connection
to acute inflammation, little is known about the functions of
miRNAs during chronic inflammation and diseases associated
with aging. Recently, the anti-inflammatory miR-146a has
emerged as a molecular safeguard against age-dependent in-
flammatory disease (Boldin et al., 2011; Zhao et al., 2011;
Zhao et al., 2013). Mice deficient in miR-146a have increased
serum concentrations of interleukin-6 (IL-6) and autoantibodies
and display splenomegaly, myeloproliferation, and inflammatory
damage to several tissues as they reach middle age. When
Mir146a/ mice grow even older, they succumb to different
types of cancers and hematopoietic neoplasms that reduce their
lifespans compared to wild-type (WT) controls. These findings
clearly demonstrate that specific miRNAs have evolved to regu-
late chronic, low-grade inflammation and establish Mir146a/
mice as an excellent model with which to study this clinically
relevant condition. Whereas miR-146a functions to prevent
chronic inflammation, we hypothesized that other miRNAs act
to promote this deleterious process.
miR-155 has emerged as a multifaceted regulator of immu-
nity that impacts different types of inflammatory responses in
young mice (Hu et al., 2013; Huffaker et al., 2012; O’Connell
et al., 2010b; Rodriguez et al., 2007; Thai et al., 2007). Further,
previous studies find that constitutive overexpression of
miR-155 in the hematopoietic compartment causes a chronicImmunity 41, 605–619, October 16, 2014 ª2014 Elsevier Inc. 605
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Figure 1. miR-155 Is Required for Expansion of CD4+ T Cells with a Tfh Cell Gene-Expression Profile in Middle-Aged Mir146a–/– Mice
(A) Spleen weights from 2 (young)- and 10 (middle-age)-month-old age- and sex-matched WT,miR155/,Mir146a/, andMir155/ Mir146a/ (DKO) mice.
(B) Representative FACS analysis of activated (CD69+CD62Llo) CD4+ T cells in the spleens and lymph nodes of 10-month-old mice.
(C) Spleen data from multiple young and middle-aged mice in (B).
(legend continued on next page)
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MicroRNAs Regulate Tfh Cells during Inflammationinflammatory disease (O’Connell et al., 2008) or leukemia
(Costinean et al., 2006), shortening the animal’s lifespan. In
the present study, we investigated the role of endogenous
miR-155 during chronic, low-grade inflammation that develops
in Mir146a/ mice.
RESULTS
miR-155-Dependent Accumulation of Activated T Cells
inMir146a–/– Mice
To determine whether endogenous miR-155 plays a role in pro-
moting age-dependent disease in Mir146a/ mice, we aged
Mir155/ Mir146a/ (DKO) and control mice for 7–10 months
(middle-age). As previously reported (Boldin et al., 2011; Zhao
et al., 2011; Zhao et al., 2013), middle-aged but not young
Mir146a/ mice had enlarged spleens (Figures 1A). Elevated
amounts of activated T cells (CD4+CD69+CD62Llo) were also
evident in middle-aged Mir146a/ mice, both in the spleen
and lymph nodes, and this activated T cell phenotype did begin
to emerge in young mice (Figures 1B and 1C; Figure S1 available
online). In contrast, middle-agedMir155/Mir146a/mice had
spleen weights and activated CD4+ T cell levels that were
similar to middle-aged WT mice, indicating that miR-155
promotes these phenotypes in Mir146a/ animals (Figures
1A–1C and S1).
The Mir146a/ mouse phenotype is largely dependent upon
lymphocytes (Zhao et al., 2013), and consistent with previous
work (Yang et al., 2012), we found that an increase in activated
CD4+ T cells precedes other disease manifestations in this
model (Figures 1C and S1). Using bone-marrow reconstitution
experiments, we also determined that this phenotype was pri-
marily hematopoietic in nature (Figure S1). On the basis of these
findings, we next assessed miR-155 expression in CD4+ T cells.
Results showed that miR-155 expression trended toward being
higher in CD4+ T cells from youngMir146a/mice, compared to
WT controls, and reached even higher expression in CD4+ T cells
taken frommiddle-agedMir146a/mice (Figure 1D). This corre-
lated with an increased proportion of activated T cells in the bulk
CD4+ T cell populations fromMir146a/ versus WT mice. Upon
sorting, we confirmed that activated CD4+ T cells expressed
higher miR-155 than naive T cells, and this expression was
enhanced further in activated T cells lacking miR-146a (Fig-
ure 1E). It has been previously demonstrated that activated
Mir146a/ CD4+ T cells have elevated NF-kB activation, a
pathway that we found to promote miR-155 expression in acti-
vated CD4+ T cells (Figure 1F). In contrast to T cells, enhanced
expression of miR-155 was not observed in B220+ B cells from(D) miR-155 expression in young and middle-aged CD4+ T cells of the indicated
(E) CD4+CD3+CD62lloCD44+ (activated) and CD4+CD3+CD62lhiCD44 (naive) cell
assayed.
(F) miR-155 expression in activated CD4+ T cells cultured with or without an NF-k
(G) Total RNA was extracted from splenic CD4+ T cells taken from 10-month-old
Gene clustering of RNA-seq data is shown. The magnitude of the gene-expressi
shown.
(H) Relative mRNA expression of IL-21, IFN-g, IL-17A, and miR-155 in CD4+ T c
(I) Heat map indicating the fold change in Tfh cell gene expression betweenMir146
is shown.
(J) qPCR analyses of Tfh-related genes in aged CD4+ T cells. The values have b
Dashed line indicates that young and middle-aged mice were harvested on diffeMir146a/ mice (Figure S1). On the basis of these results, we
focused our subsequent analysis on the CD4+ T lymphocyte
compartment to better understand the role of miR-155 during
chronic inflammation.
T Follicular Helper Cells, Germinal Center B Cells,
and Autoantibodies Accumulate in Mir146a–/– Mice
We examined gene-expression patterns in CD4+ T cells from
10-month-old WT, Mir155/, Mir146a/, and Mir155/
Mir146a/ mice by RNA-seq. Gene-expression profiles in
Mir146a/ CD4+ T cells were distinct from the other three
genotypes according to a cluster analysis while Mir155/
Mir146a/ profiles clustered closer to Mir155/ than WT or
Mir146a/ profiles (Figure 1G). IL-21 expression was signifi-
cantly higher in Mir146a/ compared to WT middle-age CD4+
T cells, while there was little difference in interferon-g (IFN-g)
mRNA amounts and undetectable expression of the IL-17A
message in both genotypes (Figure 1H). IL-21 is produced by T
follicular helper (Tfh) cells, and its elevated expression in
Mir146a/ T cells prompted us to examine additional Tfh genes.
We observed increased expression of B cell lymphoma 6 protein
(Bcl6), chemokine (C-X-Cmotif) receptor 5 (Cxcr5), programmed
cell death 1 (Pd1), and inducible T cell costimulator (Icos) in
Mir146a/ CD4+ T cells, and decreased or unchanged expres-
sion of these genes in Mir155/ and Mir155/ Mir146a/
T cells, compared to WT controls (Figure 1I). This was confirmed
by quantitative RT-PCR (qPCR) (Figure 1J). These data sug-
gested that Mir146a/ CD4+ T cells from middle-aged mice
are enriched in Tfh cells and that this occurs through a miR-
155-dependent mechanism.
Using flow cytometry, we next detected increases in CD44+
CD4+CXCR5+PD1+ Tfh cell numbers in the spleens and LNs of
middle-aged Mir146a/ mice compared to controls (Figures
2A and 2B and S2). Further, these cells also expressed ICOS
and BCL6 consistent with their Tfh cell identity (Figures 2C–
2E). miR-155 was expressed at higher amounts in WT Tfh
compared to non-Tfh cells and further enhanced in Mir146a/
Tfh cells (Figure 2F). This Tfh cell phenotype began to emerge
in young Mir146a/ mice, suggesting that it might be an early
step in disease progression. We also observed an overall in-
crease in Tfh cells in the CD4+ T cell compartment as a function
of age in all groups (Figure 2G).
Tfh cells promote antibody class-switching and production by
germinal center (GC) B cells (Johnston et al., 2009; Nurieva et al.,
2008) and play established roles in driving autoimmunity when
their development becomes dysregulated (Linterman et al.,
2009). Consistent with this, increases in B220+IgDloFashiGL7higenotypes (n = 3).
s were sorted from 10-month-old mouse spleens, andmiR-155 expression was
B inhibitor (Bay 11-7082) at the indicated concentration (2.5 or 5 mM) for 24 hr.
mice of the indicated genotypes and subjected to an RNA-seq analysis (n = 3).
on differences between any two groups is indicated by color, and the scale is
ells from middle-aged WT and Mir146a/ mice.
a/,Mir155/, orMir155/Mir146a/ compared toWT cells. The color key
een normalized to L32. * denotes a p value of < 0.05 using a Student’s t test.
rent days, and each dot represents an individual mouse. See also Figure S1.
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Figure 2. miR-155-Dependent Accumulation of Tfh Cells, GC B Cells, and Autoantibodies in Mir146a–/– Mice
(A) Flow cytometry plots showing CD4+CXCR5+PD1+ Tfh cells in the spleens of middle-aged mice.
(B) Average total number of Tfh cells in the spleens of middle-aged mice 7 to 10 months old.
(C) Flow cytometry plots showing CD4+ICOS+PD1+ Tfh cells in the spleens of middle-aged mice.
(legend continued on next page)
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mice compared to controls, and elevations in GC B cells were
also observed as a function of age in all groups (Figures 2H–
2J). Heightened serum concentrations of anti-double-stranded
DNA (dsDNA) autoantibodies were detected in middle-aged
mice, but unlike Tfh and GC B cells, not young Mir146a/
mice (Figure 2K). This suggests that in some cases, long-term
GC reactions might be necessary for production of autoanti-
bodies, which are associated with inflammation in a variety of
autoimmune settings. Of relevance, this entire phenotype was
dependent upon miR-155, as Mir155/ Mir146a/ mice
resembled WT orMir155/ animals in both age groups (Figures
2A–2D, 2G–2K and S2). These findings indicate that miR-155 is
required for spontaneous Tfh cell development and aberrant
humoral responses in Mir146a/ mice.
miR-155 Promotion of GC Formation in Mir146a–/– Mice
Precedes the Onset of Systemic Tissue Inflammation
To further assess the miR-155-dependent inflammatory disease
that develops inMir146a/ mice, H&E stained splenic sections
from WT, Mir155/, Mir146a/, and Mir155/ Mir146a/
mice at 1.5, 4, and 11 months of age were prepared (Figures
3A and S3). Immunohistochemistry (IHC) was also performed
on splenic sections from 1.5-month-old mice to detect B
(B220) and T (CD3) cells, and serial sections were also stained
for BCL6 (Figures 3B and S3). Peanut agglutinin (PNA) staining
was also performed (Figure 3C). Histological analysis demon-
strated the highest number GCs inMir146a/ spleens, reduced
amounts in WT mice, and the lowest numbers in Mir155/ and
Mir155/ Mir146a/ mice at 1.5 and 4 months of age (Figures
3A–3D). The number of GCs increased with age in WT and
Mir146a/ mice, but remained low in Mir155/ and Mir155/
Mir146a/ mice. Consistent with this, there were increased
numbers of BCL6+ and PNA+ cells in lymphoid follicles in
Mir146a/ spleens compared to spleens from the other geno-
types (Figures 3B and 3C and S3). All of these observations
are concordant with our flow cytometry data and further demon-
strate that the aberrant GCphenotype inMir146a/mice begins
in young mice and becomes more severe with age.
By 11 months of age, Mir146a/ spleens had disrupted
lymphoid follicles that were replaced by increased myeloid cells
and other hematopoietic elements, and this was generally not
observed in the other age-matched genotypes (Figures 3A and
3E and S3). Further, inflammatory infiltrates into the liver and
kidneys of Mir146a/ mice were found by 12 months of age
(Figure 3F), indicating that a multiorgan inflammatory condition
was emerging. In contrast, these features were not observed in
the Mir155/ Mir146a/ mice that were analyzed, suggesting(D) Average percentage of CD4+ICOS+PD1+ Tfh cells in the spleens of middle-ag
(E) Bcl6 expression in Tfh and non-Tfh cells in the spleens of middle-aged mice.
(F) CD4+CXCR5+PD1+ Tfh or CD4+CXCR5PD1 non-Tfh cells were sorted from
(G) Average percentage of Tfh cells in the spleens of young and middle-aged mi
(H) Flow cytometry plots showing B220+IgDloGL7hiFAShi GC B cells in the spleen
(I) Average total number of GC B cells in the spleens of middle-aged mice.
(J) Average percentage of GC B cells in the spleens of young and middle-aged m
(K) ELISA of anti-dsDNA autoantibodies in the serum of young andmiddle-aged m
that young and middle-aged mice were harvested on different days, and each
experiments. Error bars represent ± SEM. See also Figure S2.that miR-155 promotes chronic inflammation in multiple tissues
when miR-146a is absent.
miR-155 Regulates Tfh Cell Development through a
T Cell Intrinsic Mechanism following Immunization
Tfh cell formation involves both cell-intrinsic and -extrinsic
mechanisms (Tangye et al., 2013). To determine whether miR-
155 plays a cell-autonomous role in Tfh cell development, we
created T cell-specific miR-155 deficient mice (Cd4-cre
Mir155fl/fl) where the miR-155 gene is floxed and Cre is driven
by the CD4 locus (Figures 4A and 4B, Figure S4, and Table
S1). In addition to confirming specific deletion of miR-155 in
T cells (Figures 4C and S4), we also determined that Cd4-cre
Mir155fl/fl mice and controls had similar percentages of CD4+,
CD8+, and B220+ cells in the spleens under steady-state condi-
tions (Figure S4). Next, we immunized Cd4-cre Mir155fl/fl mice
and relevant controls with Ovalbumin (Ova) in complete Freund’s
adjuvant (CFA). After 8 days, we measured the development of
Tfh and GC B cells and found that miR-155 expression was spe-
cifically required by T cells for proper development of these cell
lineages in the spleen and lymph nodes (Figures 4D–4J and S5).
Further, reduced anti-Ova immunoglobulin G1 (IgG1) serum
antibodies were detected in Cd4-cre Mir155fl/fl mice at multiple
time points postimmunization (Figures 4K and 4L and S5), albeit
amounts were not as low as in whole-body Mir155/ mice
because miR-155 also functions in B cells (Rodriguez et al.,
2007; Thai et al., 2007; Vigorito et al., 2013). Despite substantial
reductions in GC phenotype B cells in the spleens of Cd4-cre
Mir155fl/fl mice, only partial decreases in antigen-specific anti-
bodies were observed, perhaps reflecting contributions or
compensation by extra follicular B cells. Together, our data
demonstrate that miR-155 has a T cell-intrinsic role during Tfh
cell development and the GC response.
miR-155 Is Required for Early Tfh Cell Differentiation by
Antigen-Specific, Naive CD4+ T Cells
To gain further insight into the role of miR-155 during Tfh cell
development, we crossed Mir155/ mice with Smarta (SM)
TCR Tg mice. Equal numbers of naive splenic WT or Mir155/
SM cells were injected into WT B6 recipients and mice were
infected with Vaccinia virus expressing the lymphocytic chorio-
meningitis virus (LCMV) glycoprotein (VACV-gpc) recognized
by SM T cells. Following 3 or 5 days of infection, Mir155/ SM
cells were defective in their production of CXCR5+PD1+ Tfh cells
compared to WT controls at both time points (Figures 5A–5C).
We also observed defective expression of BCL6 by Mir155/
SM cells at the 3-day time point (Figure 5D, top). Mir155/
SM cells demonstrated modest yet significant reductions in theed mice.
the spleens of middle-aged mice and miR-155 expression was tested.
ce.
s of middle-aged mice.
ice.
ice. * denotes a p value of < 0.05 using a Student’s t test. Dashed line indicates
dot represents an individual mouse. Data represent at least two independent
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MicroRNAs Regulate Tfh Cells during Inflammationproliferation marker Ki67 (Figure 5D, bottom), suggesting that
reduced proliferation could be contributing to their diminished
numbers compared to WT SM cells. Further,Mir155/ CXCR5+
PD1+ SM cells also displayed subtle defects in proliferation as
assayed by loss of CFSE, as fewer cells had entered the 6th
cell division by 3 days postinfection when compared to WT con-
trols (Figures 5E and 5F). No difference in SM cell death was
observed between the genotypes according to 7-AAD staining,
and homeostatic amounts of SM cells were not reduced by a
loss in miR-155 in the absence of infection (Figure S5). These
data demonstrate that naive, antigen-specific CD4+ T cells
require miR-155 for robust Tfh cell development at early stages
during the response and that miR-155 appears to influence
both Tfh cell differentiation and expansion.
Identification of miR-155 Targets in Tfh Cells
To identify miR-155 target genes involved in Tfh cell develop-
ment in the context of chronic inflammation, we utilized an inte-
grated approach (Figure S6). RNA was extracted from sorted Tfh
cells isolated 8 days after immunizing WT and Mir155/ mice
with Ova, and expression of Bcl6 was confirmed in sorted Tfh
compared to non-Tfh cells by qPCR (Figure 6A). The RNA was
next subjected to RNA-seq to profile gene expression in Wt
and Mir155/ Tfh cells, and cluster analysis revealed that the
two genotypes had disparate profiles (Figure S6). However,
expression of several Tfh-related genes was not significantly
changed between WT and Mir155/ Tfh cells on a per-cell
basis, suggesting that miR-155 regulates the quantity and not
quality of Tfh cells (Figure S6). Among miR-155 target mRNAs
predicted bioinformatically by Targetscan and determined
experimentally using Ago HITS-CLIP (Loeb et al., 2012), we
observed a bias toward higher expression of these genes in
Mir155/ versus WT Tfh cells, consistent with miR-155 target
genes being derepressed (Figures 6B and Table S2).
To identify candidate miR-155 target genes involved in Tfh cell
formation during chronic inflammation, we determined which
miR-155 targets were (1) elevated in sorted Mir155/ Tfh cells
from immunized mice (Table S2), (2) elevated in middle-aged
Mir155/ and Mir155/ Mir146a/ CD4+ T cells (Table S3),
and (3) unchanged or repressed in aged Mir146a/ CD4+
T cells. Using this stringent approach, we identified 21 candidate
miR-155 targets putatively involved in the development of Tfh
cells in Mir146a/ mice (Figures 6C and 6D). We confirmed
some of these by qPCR (Figure S6), and further validated higher
expression of Peli1, Ikbke, and Fosl2 at the protein level in
Mir155/ CD4+ T cells compared to WT controls (Figure 6E).
We also found that expression of Peli1, Fosl2, and Ikbke wasFigure 3. Histological Assessment of miR-155-Dependent, Spon
Mir146a–/– Mice
(A) Representative H&E stained sections of WT, Mir155/, Mir146a/, and Mir1
Black arrows represent examples of germinal center elements including large c
myeloid cells. Scale bar represents 40 mm.
(B) Spleen sections from 1.5-month-old mice were also subjected to IHC to dete
BCL6 positive cells. Scale bar represents 400 mm.
(C) Representative PNA staining of spleens from Mir146a/ and Mir155/ Mir1
(D) The number of GCs per splenic lymphoid follicle was determined at 1.5 and 4
(E) CD11b+ myeloid cell numbers were measured using flow cytometry.
(F) Representative H&E staining of kidneys and livers from Mir146a/ andMir15
Inflammatory infiltrate is located within the dashed boarder. * denotes a p valuelower in WT Tfh compared to non-Tfh cells taken from immu-
nized mice, whereas their expression values in Mir155/ Tfh
cells were similar to WT non-Tfh cells and well above amounts
in WT Tfh cells (Figure 6F). To confirm direct targeting of Peli1
and Fosl2, both genes that regulate T cell differentiation, we
cloned their 30 UTRs downstream from luciferase. Luciferase
assays confirmed that miR-155 directly repressed protein
expression through its binding sites in these 30 UTRs, because
repression was observed with WT 30 UTRs, but not when miR-
155 binding sites were mutated (Figures 6G and 6H).
Pathway analyses indicated that a subset of these targets
regulate the NF-kB (Ikbke and Peli1) and AP-1 (Fosl2) pathways,
both involved in Tfh cell development and autoimmunity (Chang
et al., 2011; Clark et al., 2011) (Figure 6D). Another subset of
genes repressed by miR-155 has been shown to regulate the
mTOR pathway (including Rptor, Rps6ka3, Adrb2, Ikbke, and
Nfe2l2), and there were multiple target genes involved in chro-
matin modifications (Satb1, Kat2a, Kdm7a, and Nsd1) (Fig-
ure 6D). Many of these targets have been shown to influence T
helper cell development (Figures 6D and S6).
shRNA silencing of Fosl2 in adoptively transferred Mir155/
2D2 TCR-transgenic CD4+ T cells, which are TCRVb11+, resulted
in improved Tfh cell development following immunization with
MOG35–55 (Figures 6I–6K). Silencing of Peli1 also trended toward
rescuing the phenotype, supporting our view that multiple miR-
155 targets are likely involved in this process (Figure S6). Taken
together, our findings suggest that miR-155 facilitates Tfh cell
accumulation during chronic, low-grade inflammation through
a complex mechanism involving multiple target genes and
signaling pathways that instruct early Tfh cell formation.
T Cell-Specific Expression of miR-155 Drives
Spontaneous Tfh and GC B Cell Development in
Mir146a–/– Mice
To determine the role of T cell-intrinsic miR-155 during the early
stages of chronic, low-grade inflammation, when expanded Tfh
cell populations are first observed, we crossed Mir146a/
mice with Cd4-cre Mir155fl/fl animals (Figure 7A). By 4 months
of age, Mir146a/ mice began to exhibit mild splenomegaly,
which was not seen in Mir146a/ Cd4-cre Mir155fl/fl mice (Fig-
ure 7B). Upon further analyzing 1.5- and 4-month-oldMir146a/
Cd4-cre Mir155fl/fl mice, we detected reduced numbers of Tfh
cells (Figures 7C–7J and S7) and GC B cells (Figures 7K and
7L and S7) compared to the numbers found in age-matched
Mir146a/ mice. Further, at the 4-month time point, we also
noticed that early signs of the myeloproliferative disease that
emerged as Mir146a/ mice grew older were observed intaneous GC Formation and Chronic Inflammatory Disease in
55/ Mir146a/ (DKO) male mouse spleens from mice of the indicate ages.
entroblasts, mitotic figures, and apoptotic bodies. Red arrowheads represent
ct T cells (CD3), B cells (B220), and BCL6+ cells. Arrows indicate regions with
46a/ mice at 1.5 months of age. Scale bar represents 100 mm.
months of age.
5/ Mir146a/ mice at 12 months of age. Scale bar represents 100 microns.
of < 0.05 using a Student’s t test. See also Figure S3.
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Figure 4. T Cell-Intrinsic Role for miR-155 during Tfh Cell Development and T-Dependent Humoral Responses
(A) Schematic diagram showing the loxP sites flanking the miR-155 hairpin sequence in miR-155fl/fl mice, and location of genotyping primers.
(B) Genomic DNAs were isolated from flow-cytometry-sorted CD4+CD3ε+ T and B220+ cells from the indicated mouse spleens and the primers that flank the 50
loxP site were used for PCR. A representative agarose gel is shown to demonstrate T cell specific deletion of miR-155.
(legend continued on next page)
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MicroRNAs Regulate Tfh Cells during InflammationMir146a/, but not Mir155/ Mir146a/ or Mir146a/ Cd4-
cre Mir155fl/fl mice (Figure S7). These included elevated
CD11b+ and decreased Ter119+ cells in the bone marrow.
Overall, these findings demonstrate that miR-155 plays a
T cell-intrinsic role in promoting spontaneous germinal center re-
actions in Mir146a/ mice.
DISCUSSION
The humoral response gradually loses its potency against
novel, exogenous antigens and begins to initiate responses
against self-tissues as a function of age (Dorshkind et al.,
2009; Linterman, 2014). Our study indicates that cells with a
Tfh cell phenotype might be involved in this age-dependent
conversion, because both their numbers and downstream
effects (e.g., increases in GC B cells) increase before the onset
of autoantibody production in Mir146a/ mice. This concept
is also in accordance with clinical studies that report increases
in the Tfh cell growth factors IL-6 (Akbaraly et al., 2013) and
IL-21 (Agrawal et al., 2012), memory phenotype T cells
(Moro-Garcı´a et al., 2013), autoantibodies (Nagele et al.,
2013), and autoimmune disease (Yung and Julius, 2008) in
some older versus younger individuals. During future studies,
it will be important to assess both the quality and quantity of
Tfh cell populations as a function of age in human tissues
and to determine whether different features of chronic, low-
grade inflammation in human populations involves aberrations
to this cellular population.
Mechanistically, our results identify opposing roles formiRNAs
in controlling progressive, spontaneous Tfh cell expansion,
where miR-146a restricts and miR-155 promotes this program
in mice. This suggests that factors controlling the ratio of miR-
155:miR-146a can influence this process. Both of these miRNAs
are transcriptionally induced by inflammatory stimuli or T cell re-
ceptor (TCR) engagement (Haasch et al., 2002; Yang et al.,
2012). Further, genetic variants in the miR-155 gene locus
have been linked to autoimmune disease (Paraboschi et al.,
2011), while specific polymorphisms in the passenger strand of
miR-146a lead to reduced production of mature miR-146a
(Jazdzewski et al., 2008). These observations indicate that
both genetic and environmental factors are involved in control-
ling the concentrations of these miRNAs and thus their abilities
to regulate humoral responses during the aging process.
Furthermore, while we found a variety of age-related inflamma-
tory phenotypes inMir146a/ mice to involve miR-155 through
the use of whole-bodyMir155/Mir146a/mice, and focused
on miR-155’s T cell-intrinsic role in promoting GC reactions in
this setting, future investigation is needed to determine whether
miR-155 functions in either Tfh or non-Tfh cell types to promote
other aspects of the disease that emerge in this model. It is also(C) CD4+ T, CD8+ T, and B220+ B cells were isolated from the indicated mouse sp
type was assayed by qPCR.
(D–L) The indicated mice were immunized with Ova in CFA. Following 8 days,
antibodies and analyzed by flow cytometry. (D) Representative FACS plots show
panel). (E and F) Average percentage of Tfh cells in spleens (E) and LNs (F). (G)
(H) Flow cytometry plots showing GC B cells in the spleens. (I and J) Average perc
(K and L) Relative serum amounts of Ova-specific IgG1 antibodies in OVA immun
p value of < 0.05 using a Student’s t test. Data represent at least three independplausible that other miR-146a-dependent phenotypes are inde-
pendent of miR-155.
In addition to its well-established function in B cells during Ig
class-switching and affinity hypermutation (Rodriguez et al.,
2007; Thai et al., 2007; Vigorito et al., 2007), our data identify a
previously unappreciated role for miR-155 in the CD4+ T cells
as they provide help to B cells during the germinal center reac-
tion. In particular, we describe a decreased capacity by
Mir155/ CD4+ T cells to develop into the Tfh cell lineage
following immunization, viral infection, or during age-related in-
flammatory disease. Because we observe decreased Tfh cell
numbers, while our expression analysis indicates that effector
function might be intact on a per cell basis, it is possible that
miR-155 is involved in Tfh cell differentiation and expansion as
opposed to their functions once mature. Our findings also indi-
cate that multiple miRNAs are involved in regulating Tfh cell
biology, as recent studies have described roles for the miRNAs
1792 family (Baumjohann et al., 2013; Kang et al., 2013) and
miR-10a (Takahashi et al., 2012) during Tfh cell formation.
We identified 21 direct miR-155 targets in Tfh cells that regu-
late critical signaling pathways including NF-kB, AP-1, and
mTor, in addition to several genes that regulate chromatin mod-
ifications. Consistent withmany previous studies (Hu et al., 2013;
Huffaker et al., 2012; Loeb et al., 2012), our results continue to
support a model whereby miR-155 regulates T cell biology
through a multitarget mechanism that enables development of
different T effector cell subsets in distinct contexts. However, it
remains unclear whether miR-155 targets unique sets of genes
to regulate the distinct effector T cell lineages that it has been
linked to, including regulatory T (Treg) cells (Lu et al., 2009),
Th17 cells (Kurowska-Stolarska et al., 2011; O’Connell et al.,
2010b), Th1 cells (Oertli et al., 2011), Th2 cells (Malmhall et al.,
2013), and now Tfh cells, or whether there is a core ‘‘targetome’’
that is commonly required to license the formation of these sub-
types. This will be an important area of future research that will
require target identification in multiple T cell types in parallel
using the same technology.
Our data also provide evidence that Fosl2, and to some extent
Peli1, are functionally relevant miR-155 targets. Fosl2 is a
repressor of CD4+ T cell plasticity (Ciofani et al., 2012) that binds
to Jun proteins and is thought to compete with Batf for DNA
binding sites. Batf-containing AP-1 complexes bind coopera-
tively with IRF4 to defined DNA elements called AP-1-IRF com-
posite elements (AICEs) (Glasmacher et al., 2012), and both of
these factors are necessary for Tfh cell development (Betz
et al., 2010; Bollig et al., 2012). However, Fosl2-containing com-
plexes are unable to recruit IRF4 once bound to these sites
(Glasmacher et al., 2012), pointing to a mechanistic basis for
its repressive role during T cell differentiation. Thus, because
Fosl2 is at higher amounts in Mir155/ CD4+ T cells, our dataleens by flow cytometry sorting and expression of mature miR-155 by each cell
spleens and LNs were isolated and subjected to staining with the indicated
ing CD4+CXCR5+PD1+ Tfh cells in the spleens (upper panel) and LNs (lower
Bcl6 expression in Tfh and non-Tfh cells in the spleens of the indicated mice.
entage (I) or total number (J) of B220+IgDloFashiGL7hi GC B cells in the spleens.
ized mice from the indicated time points and genotypes (D = Day). * denotes a
ent experiments. See also Figures S4 and S5.
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Figure 5. Robust Tfh Cell Differentiation by Naive Antigen Specific CD4+ T Cells in Response to VACV-gpc Infection Requires miR-155
8 3 104 (D3) or 2 3 104 (D5) WT or Mir155/ SM cells were transferred into B6 WT mice, which were infected with VACV-gpc the following day. Mice were
analyzed at D3 or D5 postinfection.
(A and B) Representative flow cytometry plots showing the percentage of WT andMir155/ CD4+Thy1.1+ SM cells (left panel) and percentage of CXCR5+PD1+
Tfh cells within this population (right panel), in the spleens at the indicated time point.
(C) Average percentage of SM T cells, or Tfh cells within this population, in the spleens at the indicated time points postinfection.
(D) Representative histogram of Bcl6 or Ki67 staining of WT or Mir155/ SM cells at the 3-day time point. The average MFI of each stain is shown to the right.
(E) Representative histogram showing CFSE expression by WT or Mir155/ SM Tfh cells at 3 days postinfection.
(F) The average percentage of Tfh cells having entered the 6th cell division. * denotes a p value of < 0.05 using a Student’s t test. Data represent at least two
independent experiments. See also Figure S5.
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MicroRNAs Regulate Tfh Cells during Inflammationsuggest that it is able to hinder Tfh cell development by inter-
fering with normal Batf and IRF4 functions. In the case of Peli1,
it has been shown to inhibit NF-kB activation, which is also614 Immunity 41, 605–619, October 16, 2014 ª2014 Elsevier Inc.involved in the induction of Tfh cell-associated genes (Chang
et al., 2011; Chen et al., 2010). Future work will investigate these
connections further and determine their relevance in other Th cell
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Immunity
MicroRNAs Regulate Tfh Cells during Inflammationlineages, including Th17 and Treg cells wheremiR-155 and Fosl2
have been shown to have opposing functions.
Finally, our observations have many translational implications
with relevance to human disease. First, the relative expression of
miR-155 and miR-146a in middle-aged individuals might have
predictive, diagnostic, or prognostic value in the context of
chronic, low-grade inflammation. Next, therapeutic targeting of
miR-155 or miR-146a with antisense oligonucleotides in patients
with chronic, low-grade inflammation could be an effective strat-
egy to reduce certain disorders that stem from aberrant humoral
responses. Conversely, from a vaccine development standpoint,
these findings indicate that manipulation of miR-155 in both T
and B cells might have a synergistic effect on the production of
high affinity, class-switched antibodies that can be induced via
immunization to target tumor cells or pathogenic microbes.
EXPERIMENTAL PROCEDURES
Mice
All experiments were approved by the University of Utah Institutional Animal
Care and Use Committee (IACUC). Mir155/ Mir146a/ (DKO) mice were
generated as previously described (Huffaker et al., 2012). Mir155fl/fl mice
were generated at Taconic and crossed with Cd4-cre mice to create Cd4-
cre Mir155fl/fl mice. Additionally, Mir146a/ mice were crossed with Cd4-
cre Mir155fl/fl mice to generate Mir146a/ Cd4-cre Mir155fl/fl mice, and Wt
SMARTA TCR Tg+ mice were crossed with Mir155/ mice to generate
Mir155/ SMARTA TCR Tg+. Mir155/ 2d2 TCR Tg+ mice were described
previously (Hu et al., 2013).
Flow Cytometry
Fluorophor-conjugated antibodies against the indicated surface markers were
used to stain RBC-depleted splenocytes, LN cells, BM cells, and peripheral
blood cells. For intracellular staining, cells were first surface stained for lineage
markers and then fixed, permeabilized, and stained with antibodies against
Bcl6, IL-17A, IFN-g, or Ki67 (BioLegend). Stained cells were analyzed with a
BD LSR Fortessa flow cytometer, and further data analysis was carried out
with FlowJo software.
Bone-Marrow Reconstitution
RBC-depleted bone-marrow cells from WT mice expressing the congenic
marker CD45.1 were mixed with bone marrow from WT, miR155/,
Mir146a/, or Mir155/ Mir146a/ mice expressing CD45.2 in equal pro-
portions and injected into lethally irradiated (1,050 Rads) WT mice expressing
CD45.1, similar to (O’Connell et al., 2010a).Figure 6. Identification of Tfh Cell-Relevant miR-155 Target Genes in C
(A) qPCR analyses of mature miR-155 and BCL6 mRNA expression in sorted Tfh
(B) Pie charts indicating the percentage of genes that are upregulated (>1.2) or do
data set or specifically miR-155 target genes.
(C) Venn diagram showing the number of common miR-155 targets in purified Tf
(D) Genes targeted bymiR-155 according to the overlap in (C). Bars represent relat
based on RNA-seq data. Boxes indicate different pathways in which these gene
differentiation.
(E) Representative immunoblot analysis of Peli1, Ikbke, Fosl2, and a-tubulin expre
(n = 9), Ikbke (n = 6), and Fosl2 (n = 4) expression in T cells from multiple mice n
(F) Relative expression of Fosl2, Peli1, and Ikbke in sorted CD4+ non-Tfh and Tfh
(G) Luciferase reporter assays demonstrating direct repression of the 30 UTRs by
(H) Schematic layout of the 30 UTR sequence of mouse Fosl2 and Peli1 and the
shown in green.
(I) Representative immunoblot analysis of Fosl2 expression in activated WT CD4
(J) Representative flow cytometry plots showing the percentage of CXCR5+PD1+
immunization with MOG35–55.
(K) Average percentage of Tfh cells among CD3+CD4+Vb11+GFP+ cells from (I). Er
See also Figure S6.
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Untouched naive (Thy1.1+CD44lo) CD4+ T cells were isolated from WT or
Mir155/ SMARTAmice (SM T cells) using magnetic beads, per themanufac-
turer’s instructions (Stem Cell Technology), and injected intravenously into
C57BL/6 mice. The next day, mice were infected with recombinant Vaccinia
virus that expresses the LCMV glycoprotein (referred to as VACV-gpc). For
CFSE labeling, T cells were incubated with 0.625 mM CFSE (final concentra-
tion) for 10 min and washed with FBS before adoptive transfer. To determine
viability, we used 7-AAD staining.
Adoptive Transfer of shRNA-Expressing 2d2 TCR Tg CD4+ T Cells
and MOG35–55 Immunization
Untouched naive CD44lo CD4+ T cells were injected intravenously into B6mice
following spin infection with control or shRNA retroviral vectors, as described
(Hu et al., 2013). The sequences targeting Fosl2 and Peli1 are shown in Table
S4. The next day, the mice were immunized with MOG35–55 (0.5 mg/ml) emul-
sified in complete Freund’s adjuvant (CFA) at the base of the tail (200 ml each
mouse), as described (Hu et al., 2013).
ELISAs
Titers of autoantibodies against dsDNA in the serum of aged mice were
measured with a commercial ELISA test (BioVendor) according to the
manufacturer’s protocol. Serum from Ova-immunized mice (0.5 mg/ml
emulsified in CFA) was also collected, and Ova antigen-specific IgG and
IgG1 antibodies were measured by ELISA, as described (O’Connell et al.,
2010b).
qPCR
Sybrgreen-based quantitative real-time PCR was conducted to assay relative
mRNA amounts with the Light Cycler 480 PCR system (Roche) and gene-
specific primers (Table S4). For mature miR-155 and miR-146a expression
analyses, gene-specific primers were purchased from Exiqon. 5S or L32
were used to normalize.
RNA Sequencing
For both experiments, total RNA was isolated with themiRNeasy kit (QIAGEN).
Stranded RNA sequencing (following RiboZero treatment and library prepara-
tion) was conducted using Illumina HiSeq 2000 Sequencing and carried out
by the University of Utah core facility (https://bioserver.hci.utah.edu/
microarrayweb/ordering.html). The analysis approach is described in our Sup-
plemental Experimental Procedures.
Immunoblotting
Cell extracts were subjected to gel electrophoresis and transferred onto a
nitrocellulose membrane followed by antibody staining and detection of
Peli1, Ikbke, Fosl2, b-actin, or a-tubulin, as described (Hu et al., 2013).D4+ T Cells from Middle-Aged Mice
and non-Tfh cells from the indicated mouse spleens following immunization.
wnregulated (<0.8) inMir155/ versus WT Tfh cells based on all genes in the
h cells and CD4+ T cells from middle-aged mice.
ive fold change of gene expression in themutant cells compared toWT controls
s function, and * denotes that a role for the gene has been described in T cell
ssion in activated WT andMir155/ CD4+ T cells (left). Quantification of Peli1
ormalized to a-tubulin (right).
cells from OVA-immunized WT and Mir155/ mice based on RNA-seq.
miR-155. For Fosl2, the mutant 30 UTR has both sites disrupted.
seed region (yellow) where miR-155 is predicted to bind. Mutant sequence is
+ T cells after silencing with a shFosl2 expressing retroviral vector.
Tfh cells among CD3+CD4+Vb11+GFP+ cells in the spleens following 7 days of
ror bars represent ± SEM. * denotes a p value of < 0.05 using a Student’s t test.
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Immunity
MicroRNAs Regulate Tfh Cells during InflammationLuciferase Assay
The 30 UTR regions of mouse Fosl2 and Peli1 that contain the miR-155 binding
sites, or mutant versions, were synthesized byGeneArt Technology (Life Tech-
nologies) and cloned into pMiR reporter plasmid. Experiments were performed
with 293T cells, as described (Hu et al., 2013).
Histological Analyses
Tissue preparation and H&E staining were performed as described previously
(O’Connell et al., 2008). IHC was performed with antibodies against B220,
CD3, and BCl6 or PNA.
Statistical Analysis
Statistical significance was determined by performing an unpaired t test
with Graphpad Prism. All quantitative data are reported as mean ± SEM or
mean. Significance is denoted as ***p % 0.001, **p % 0.01, *p % 0.05, and
ns p > 0.05.
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(G–J) Average values for multiple mice from (C)–(F).
(K) Flow cytometry plots showing B220+IgDloFashiGL7hi GC B cells in the spleen
(L) Average total number of GCB cells in the spleens from (K). Error bars represent
independent experiments. See also Figure S7.
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